Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults
- 2 March 2010
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 28 (10), 2236-2242
- https://doi.org/10.1016/j.vaccine.2009.12.049
Abstract
No abstract availableKeywords
Funding Information
- Intramural Division of the National Institutes of Health, National Institute of Allergy and Infectious Diseases
- PATH Malaria Vaccine Initiative
This publication has 30 references indexed in Scilit:
- A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel® with CPG 7909, using two different formulations and dosing intervalsVaccine, 2009
- A randomized controlled phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in children in MaliVaccine, 2009
- Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of AgeNew England Journal of Medicine, 2008
- Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum MalariaPLOS ONE, 2008
- Safety and Immunogenicity of a Malaria Vaccine, Plasmodium falciparum AMA-1/MSP-1 Chimeric Protein Formulated in Montanide ISA 720 in Healthy AdultsPLOS ONE, 2008
- Phase 1 Study of a Combination AMA1 Blood Stage Malaria Vaccine in Malian ChildrenPLOS ONE, 2008
- Safety and Immunogenicity of an AMA-1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled TrialPLOS ONE, 2008
- Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccinesVaccine, 2007
- Impact of a Plasmodium falciparum AMA1 Vaccine on Antibody Responses in Adult MaliansPLOS ONE, 2007
- Structural basis of antigenic escape of a malaria vaccine candidateProceedings of the National Academy of Sciences of the United States of America, 2007